Expression of phosphorylated Hippo pathway kinases (MST1/2 and LATS1/2) in HER2-positive and triple-negative breast cancer patients treated with neoadjuvant therapy

References

• Johnson R, Halder G. The two faces of Hippo: targeting the Hippo pathway for regenerative medicine and cancer treatment. Nat Rev Drug Discov 2014; 13:63-79; PMID:24336504; https://doi.org/10.1038/nrd4161
   PubMed Web of Science ®Google Scholar
• Piccolo S, Dupont S, Cordenonsi M. The biology of YAP/TAZ: hippo signaling and beyond. Physiol Rev 2014; 94:1287-312; PMID:25287865; https://doi.org/10.1152/physrev.00005.2014
   PubMed Web of Science ®Google Scholar
• Maugeri-Saccà M, Barba M, Pizzuti L, Vici P, Di Lauro L, Dattilo R, Vitale I, Bartucci M, Mottolese M, De Maria R. The Hippo transducers TAZ and YAP in breast cancer: oncogenic activities and clinical implications. Expert Rev Mol Med 2015; 17:e14; PMID:26136233; https://doi.org/10.1017/erm.2015.12
   PubMed Web of Science ®Google Scholar
• Maugeri-Saccà M, De Maria R. Hippo pathway and breast cancer stem cells. Crit Rev Oncol Hematol 2016; 99:115-22; PMID:26725175; https://doi.org/10.1016/j.critrevonc.2015.12.004
   PubMed Web of Science ®Google Scholar
• Bartucci M, Dattilo R, Moriconi C, Pagliuca A, Mottolese M, Federici G, Benedetto AD, Todaro M, Stassi G, Sperati F, et al. TAZ is required for metastatic activity and chemoresistance of breast cancer stem cells. Oncogene 2015; 34:681-90; PMID:24531710; https://doi.org/10.1038/onc.2014.5
   PubMed Web of Science ®Google Scholar
• Cordenonsi M, Zanconato F, Azzolin L, Forcato M, Rosato A, Frasson C, Inui M, Montagner M, Parenti AR, Poletti A, et al. The Hippo transducer TAZ confers cancer stem cell-related traits on breast cancer cells. Cell 2011; 147:759-72; PMID:22078877; https://doi.org/10.1016/j.cell.2011.09.048
   PubMed Web of Science ®Google Scholar
• Xiang L, Gilkes DM, Hu H, Takano N, Luo W, Lu H, Bullen JW, Samanta D, Liang H, Semenza GL. Hypoxia-inducible factor 1 mediates TAZ expression and nuclear localization to induce the breast cancer stem cell phenotype. Oncotarget 2014; 5:12509-27; PMID:25587023; https://doi.org/10.18632/oncotarget.2997
   PubMed Web of Science ®Google Scholar
• Chang C, Goel HL, Gao H, Pursell B, Shultz LD, Greiner DL, Ingerpuu S, Patarroyo M, Cao S, Lim E, et al. A laminin 511 matrix is regulated by TAZ and functions as the ligand for the α6Bβ1 integrin to sustain breast cancer stem cells. Genes Dev 2015; 29:1-6; PMID:25561492; https://doi.org/10.1101/gad.253682.114
   PubMed Web of Science ®Google Scholar
• Nandy SB, Arumugam A, Subramani R, Pedroza D, Hernandez K, Saltzstein E, Lakshmanaswamy R. MicroRNA-125a influences breast cancer stem cells by targeting leukemia inhibitory factor receptor which regulates the Hippo signaling pathway. Oncotarget 2015; 6:17366-78; PMID:25962054; https://doi.org/10.18632/oncotarget.3953
   PubMed Web of Science ®Google Scholar
• Vici P, Mottolese M, Pizzuti L, Barba M, Sperati F, Terrenato I, Di Benedetto A, Natoli C, Gamucci T, Angelucci D, et al. The Hippo transducer TAZ as a biomarker of pathological complete response in HER2-positive breast cancer patients treated with trastuzumab-based neoadjuvant therapy. Oncotarget 2014; 5:9619-25; PMID:25294813; https://doi.org/10.18632/oncotarget.2449
   PubMed Web of Science ®Google Scholar
• Vici P, Ercolani C, Di Benedetto A, Pizzuti L, Di Lauro L, Sperati F, Terrenato I, Gamucci T, Natoli C, Di Filippo F, et al. Topographic expression of the Hippo transducers TAZ and YAP in triple-negative breast cancer treated with neoadjuvant chemotherapy. J Exp Clin Cancer Res 2016; 35:62; PMID:27039292; https://doi.org/10.1186/s13046-016-0338-7
   PubMed Web of Science ®Google Scholar
• Di Benedetto A, Mottolese M, Sperati F, Ercolani C, Di Lauro L, Pizzuti L, Vici P, Terrenato I, Sperduti I, Shaaban AM, et al. The Hippo transducers TAZ/YAP and their target CTGF in male breast cancer. Oncotarget 2016; 7(28):43188-98. [Epub ahead of print].
   PubMed Web of Science ®Google Scholar
• Du X, Yu A, Tao W. The non-canonical Hippo/Mst pathway in lymphocyte development and functions. Acta Biochim Biophys Sin (Shanghai) 2015; 47:60-4; PMID:25487919; https://doi.org/10.1093/abbs/gmu112
   PubMed Web of Science ®Google Scholar
• Pefani DE, O'Neill E. Hippo pathway and protection of genome stability in response to DNA damage. FEBS J 2016; 283:1392-403; PMID:26607675; https://doi.org/10.1111/febs.13604
   PubMed Web of Science ®Google Scholar
• Jeggo PA, Pearl LH, Carr AM. DNA repair, genome stability and cancer: a historical perspective. Nat Rev Cancer 2016; 16:35-42; PMID:26667849; https://doi.org/10.1038/nrc.2015.4
   PubMed Web of Science ®Google Scholar
• Vici P, Di Benedetto A, Ercolani C, Pizzuti L, Di Lauro L, Sergi D, Sperati F, Terrenato I, Dattilo R, Botti C, et al. Predictive significance of DNA damage and repair biomarkers in triple-negative breast cancer patients treated with neoadjuvant chemotherapy: An exploratory analysis. Oncotarget 2015; 6(40):42773-80; PMID:26544894; https://doi.org/10.18632/oncotarget.6001
   PubMed Web of Science ®Google Scholar
• Díaz-Martín J, López-García MÁ, Romero-Pérez L, Atienza-Amores MR, Pecero ML, Castilla MÁ, Biscuola M, Santón A, Palacios J. Nuclear TAZ expression associates with the triple-negative phenotype in breast cancer. Endocr Relat Cancer 2015; 22(3):443-54; PMID:25870251; https://doi.org/10.1530/ERC-14-0456
   PubMed Web of Science ®Google Scholar
• Salgado R, Denkert C, Demaria S, Sirtaine N, Klauschen F, Pruneri G, Wienert S, Van den Eynden G, Baehner FL, Penault-Llorca F, et al. The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014. Ann Oncol 2015; 26:259-71; PMID:25214542; https://doi.org/10.1093/annonc/mdu450
   PubMed Web of Science ®Google Scholar
• Salgado R, Denkert C, Campbell C, Savas P, Nuciforo P, Aura C, de Azambuja E, Eidtmann H, Ellis CE, Baselga J, et al. Tumor-infiltrating lymphocytes and associations with pathological complete response and event-free survival in HER2-positive early-stage breast cancer treated with lapatinib and trastuzumab: a secondary analysis of the NeoALTTO trial. JAMA Oncol 2015; 1:448-54; PMID:26181252; https://doi.org/10.1001/jamaoncol.2015.0830
   PubMed Web of Science ®Google Scholar
• Denkert C, Loibl S, Noske A, Roller M, Müller BM, Komor M, Budczies J, Darb-Esfahani S, Kronenwett R, Hanusch C, et al. Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer. J Clin Oncol 2010; 28:105-113; PMID:19917869; https://doi.org/10.1200/JCO.2009.23.7370
   PubMed Web of Science ®Google Scholar
• Buglioni S, Vici P, Sergi D, Pizzuti L, Di Lauro L, Antoniani B, Sperati F, Terrenato I, Carosi M, Gamucci T, et al. Analysis of the hippo transducers TAZ and YAP in cervical cancer and its microenvironment. Oncoimmunology 2016; 5:e1160187; PMID:27471633; https://doi.org/10.1080/2162402X.2016.1160187
   PubMed Web of Science ®Google Scholar
• Teng MW, Ngiow SF, Ribas A, Smyth MJ. Classifying cancers based on T-cell infiltration and PD-L1. Cancer Res 2015; 75(11):2139-45; PMID:25977340; https://doi.org/10.1158/0008-5472.CAN-15-0255
   PubMed Web of Science ®Google Scholar
• Hamilton G, Yee KS, Scrace S, O'Neill E. ATM regulates a RASSF1A-dependent DNA damage response. Curr Biol 2009; 19:2020-5; PMID:19962312; https://doi.org/10.1016/j.cub.2009.10.040
   PubMed Web of Science ®Google Scholar
• Matsuoka S, Ballif BA, Smogorzewska A, McDonald ER 3rd, Hurov KE, Luo J, Bakalarski CE, Zhao Z, Solimini N, Lerenthal Y, et al. ATM and ATR substrate analysis reveals extensive protein networks responsive to DNA damage. Science 2007; 316:1160-6; PMID:17525332; https://doi.org/10.1126/science.1140321
   PubMed Web of Science ®Google Scholar
• Pefani DE, Latusek R, Pires I, Grawenda AM, Yee KS, Hamilton G, van der Weyden L, Esashi F, Hammond EM, O'Neill E.. RASSF1A-LATS1 signalling stabilizes replication forks by restricting CDK2-mediated phosphorylation of BRCA2. Nat Cell Biol 2014; 16:962-71; PMID:25218637; https://doi.org/10.1038/ncb3035
   PubMed Web of Science ®Google Scholar
• Aylon Y, Yabuta N, Besserglick H, Buganim Y, Rotter V, Nojima H, Oren M. Silencing of the Lats2 tumor suppressor overrides a p53-dependent oncogenic stress checkpoint and enables mutant H-Ras-driven cell transformation. Oncogene 2009; 28:4469-79; PMID:19855428; https://doi.org/10.1038/onc.2009.270
   PubMed Web of Science ®Google Scholar
• Zhou X, Wang S, Wang Z, Feng X, Liu P, Lv XB, Li F, Yu FX, Sun Y, Yuan H, et al. Estrogen regulates Hippo signaling via GPER in breast cancer. J Clin Invest 2015; 125:2123-35; PMID:25893606; https://doi.org/10.1172/JCI79573
   PubMed Web of Science ®Google Scholar
• Lin CH, Pelissier FA, Zhang H, Lakins J, Weaver VM, Park C, LaBarge MA. Microenvironment rigidity modulates responses to the HER2 receptor tyrosine kinase inhibitor lapatinib via YAP and TAZ transcription factors. Mol Biol Cell 2015; 26:3946-53; PMID:26337386; https://doi.org/10.1091/mbc.E15-07-0456
   PubMed Web of Science ®Google Scholar
• Gaillard H, García-Muse T, Aguilera A. Replication stress and cancer. Nat Rev Cancer 2015; 15:276-289; PMID:25907220; https://doi.org/10.1038/nrc3916
   PubMed Web of Science ®Google Scholar
• Vitale I, Galluzzi L, Castedo M, Kroemer G. Mitotic catastrophe: a mechanism for avoiding genomic instability. Nat Rev Mol Cell Biol 2011; 12:385-92; PMID:21527953; https://doi.org/10.1038/nrm3115
   PubMed Web of Science ®Google Scholar
• von Minckwitz G, Schneeweiss A, Loibl S, Salat C, Denkert C, Rezai M, Blohmer JU, Jackisch C, Paepke S, Gerber B, et al. Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto;GBG 66): A randomised phase 2 trial. Lancet Oncol 2014; 15:747-56; PMID:24794243; https://doi.org/10.1016/S1470-2045(14)70160-3
   PubMed Web of Science ®Google Scholar
• Sikov WM, Berry DA, Perou CM, Singh B, Cirrincione CT, Tolaney SM, Kuzma CS, Pluard TJ, Somlo G, Port ER, et al. Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dosedense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40603 (Alliance). J Clin Oncol 2015; 33:13-21; PMID:25092775; https://doi.org/10.1200/JCO.2014.57.0572
   PubMed Web of Science ®Google Scholar